This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Quetiapine Fumarate Bipolar Maintenance Monotherapy (SPaRCLe)

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: April 11, 2006
Last updated: December 19, 2008
Last verified: December 2008
April 11, 2006
December 19, 2008
March 2005
Not Provided
Time from randomization to recurrence of a mood event
Same as current
Complete list of historical versions of study NCT00314184 on Archive Site
  • Time from randomization to recurrence of a manic event
  • Time from randomization to recurrence of a depressed event
Same as current
Not Provided
Not Provided
Quetiapine Fumarate Bipolar Maintenance Monotherapy
Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 Weeks Maintenance Treatment of Bipolar I Disorder in Adult Patients

This is a multicenter, randomized, parallel-group, double-blind, placebo-controlled study to evaluate the efficacy and safety of quetiapine and lithium (comparator in the study) for up to 104 weeks of maintenance treatment in adult patients with Bipolar I Disorder.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Bipolar Disorder
Drug: quetiapine fumarate
Other Name: Seroquel
Not Provided
Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B; Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry. 2011 Nov;72(11):1452-64. doi: 10.4088/JCP.11m06878. Erratum in: J Clin Psychiatry. 2014 Mar;75(3):290.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
July 2007
Not Provided

Inclusion Criteria:

  • Signed informed consent
  • 18 years or older
  • A diagnosis of Bipolar I Disorder
  • Have a current manic, depressed or mixed episode
  • Have had a manic, depressed or mixed episode during the last 26 weeks that was treated with quetiapine
  • Female patients of childbearing potential must be using a reliable method of contraception

Exclusion Criteria:

  • Pregnancy
  • Substance or alcohol dependence at enrollment
  • Unstable thyroid function
  • Unstable Diabetes
  • Unstable or inadequately treated medical illness e.g., angina pectoris and hypertension
  • Use of an experimental drug within 30 days of enrollment
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Colombia,   Argentina,   Bulgaria,   India,   Lithuania,   Malaysia,   Mexico,   Peru,   Philippines,   Romania,   Russian Federation,   Taiwan,   Thailand,   Ukraine,   United States
EUDRACT 2004-000915-25
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
Study Director: AstraZeneca CNS Medical Science Director, MD AstraZeneca
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP